Blue Sky Health Sector Stock Volatility Report

Notable Movers & Volatility

MRNA dominated the tape, running +235.47% from $52.66 to $176.66 and finishing at $140.68 — 70.98% of its range, well off the high but still a +155.60% period return. Its 5.91x realized/implied ratio was the largest vol surprise in the set: options priced 184.50% vol against 374.98% realized. KPTI was the mirror image, -75.97% to $1.79 and closing at just 1.49% of range with 414.98% realized vol.

Underpricing was widespread. SYK (3.79x), STIM (3.39x), BNTX (3.36x), TEM (3.25x), CI (3.17x) and MRK (3.02x) all realized far more movement than implied levels suggested. The exceptions were the highest-IV names: CDXS (0.50x, 216.41% implied) and DBVT (0.42x, 166.21% implied) saw premium go unrewarded.

Range placement split cleanly. Gainers closed near highs — TEM 97.33%, MRK 94.17%, ABT 94.76%, HIMS 91.37%. Decliners closed near lows — CVS 3.06%, UNH 2.96%, EBS 7.19%. Managed-care names (UNH, CI, CVS, HUM) were uniformly weak, while ABBV closed at 93.11% of range despite a -9.82% change.

Broader Market Context

Differential behavior within the sector. The dispersion here is extreme even by healthcare standards — roughly 311 percentage points separate MRNA (+235.47%) from KPTI (-75.97%). The sector broke into recognizable sub-groups rather than moving as a bloc:

• Biotech/vaccine names (MRNA, BNTX +31.52%, QURE +28.99%) posted outsized gains with realized vol of 48–375%.
• Large-cap pharma (MRK +21.61%, AMGN +17.88%, LLY +16.54%, GILD +16.13%, ABT +12.42%, JNJ +10.39%) advanced in a tight, orderly 10–22% band with realized vol mostly in the 20–45% range.
• Managed care/payers (UNH -10.65%, CI -13.17%, CVS -15.45%, HUM -10.53%) were the sector's clear losers, all closing in the lower half of their ranges.
• Micro-cap biotech (KPTI, EBS -43.38%, CDXS, DBVT, MGNX) behaved idiosyncratically, with vol ratios ranging from 0.42x to 5.08x.

XLV's +9.87% gain and 22.28% realized vol sits well below the individual-name averages, confirming the sector ETF masked enormous internal dispersion.

Rotation vs. idiosyncratic moves. The pattern looks like a hybrid. The broad, correlated lift across large-cap pharma and XLV — with providers like THC (+13.63%) and ADUS (+14.50%) also higher — is consistent with money rotating *into* healthcare, plausibly a defensive positioning shift. But the payer weakness cuts directly against that read: if this were a clean defensive rotation, managed care would likely have participated. The simultaneous collapse in UNH, CI, CVS and HUM is more consistent with a sub-industry-specific repricing than with sector-level flows. Meanwhile MRNA, KPTI and EBS moved far too violently to be explained by rotation at all; those look stock-specific.

Plausible current drivers. Without asserting particular events, several themes could reasonably relate:

• Policy and reimbursement risk disproportionately affecting insurers — cost-trend or rate-setting concerns would explain payer underperformance while leaving pharma untouched.
• Clinical or regulatory catalysts in biotech, where 3x–6x realized/implied ratios are typical of binary trial or approval outcomes.
• Rate and dollar dynamics, which tend to support long-duration pharma cash flows.
• M&A speculation, plausible given mid-cap strength in TEM (+67.24%) and ANAB (+19.40%).

The near-universal underpricing of realized vol suggests options markets entered the period positioned for a calmer sector than materialized.